Literature DB >> 19302482

Protection of midbrain dopaminergic neurons by the end-product of purine metabolism uric acid: potentiation by low-level depolarization.

Serge Guerreiro1, Aurélie Ponceau, Damien Toulorge, Elodie Martin, Daniel Alvarez-Fischer, Etienne C Hirsch, Patrick P Michel.   

Abstract

High plasma levels of the end product of purine metabolism uric acid (UA) predict a reduced risk of developing Parkinson's disease suggesting that UA may operate as a protective factor for midbrain dopaminergic neurons. Consistent with this view, UA exerted partial but long-term protection in a culture model in which these neurons die spontaneously. The rescued neurons were functional as they accumulated dopamine, efficiently. The use of the fluorescent probe dihydrorhodamine-123 revealed that UA operated by an antioxidant mechanism. The iron chelating agent desferrioxamine, the H(2)O(2) scavenger enzyme catalase and the inhibitor of lipid peroxidation Trolox mimicked the effects of UA, suggesting that UA neutralized reactive oxygen species produced via a Fenton-type chemical reaction. UA was, however, not significantly accumulated into neurons, which indicates that the antioxidant effect occurred probably extracellularly. Structure - activity relationships among purine derivatives revealed that the antioxidant properties of UA resulted from the presence of a 8-one substituent in its chemical structure. Of interest, the stimulation of L-type Ca(2+) channels by high K(+)-induced depolarization and the ensuing activation of extracellular signal-regulated kinases 1/2 strongly improved the neuroprotective effect of UA whereas the depolarizing signal alone had no effect. In summary, our data indicate that UA may interfere directly with the disease's pathomechanism.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19302482     DOI: 10.1111/j.1471-4159.2009.06040.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  36 in total

1.  Allopurinol reduces levels of urate and dopamine but not dopaminergic neurons in a dual pesticide model of Parkinson's disease.

Authors:  Anil Kachroo; Michael A Schwarzschild
Journal:  Brain Res       Date:  2014-03-26       Impact factor: 3.252

2.  Uric acid: a danger signal from the RNA world that may have a role in the epidemic of obesity, metabolic syndrome, and cardiorenal disease: evolutionary considerations.

Authors:  Richard J Johnson; Miguel A Lanaspa; Eric A Gaucher
Journal:  Semin Nephrol       Date:  2011-09       Impact factor: 5.299

3.  Homeostatic imbalance of purine catabolism in first-episode neuroleptic-naïve patients with schizophrenia.

Authors:  Jeffrey K Yao; George G Dougherty; Ravinder D Reddy; Matcheri S Keshavan; Debra M Montrose; Wayne R Matson; Joseph McEvoy; Rima Kaddurah-Daouk
Journal:  PLoS One       Date:  2010-03-03       Impact factor: 3.240

Review 4.  Targeting urate to reduce oxidative stress in Parkinson disease.

Authors:  Grace F Crotty; Alberto Ascherio; Michael A Schwarzschild
Journal:  Exp Neurol       Date:  2017-06-13       Impact factor: 5.330

5.  Assessment of serum uric acid as risk factor for tauopathies.

Authors:  Tommaso Schirinzi; Giulia Di Lazzaro; Vito Luigi Colona; Paola Imbriani; Mohammad Alwardat; Giulia Maria Sancesario; Alessandro Martorana; Antonio Pisani
Journal:  J Neural Transm (Vienna)       Date:  2017-06-15       Impact factor: 3.575

6.  Plasma urate and Parkinson's disease in women.

Authors:  Eilis J O'Reilly; Xiang Gao; Marc G Weisskopf; Honglei Chen; Michael A Schwarzschild; Donna Spiegelman; Alberto Ascherio
Journal:  Am J Epidemiol       Date:  2010-08-02       Impact factor: 4.897

Review 7.  Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view.

Authors:  Jeffrey K Yao; Matcheri S Keshavan
Journal:  Antioxid Redox Signal       Date:  2011-04-21       Impact factor: 8.401

8.  Impulsivity is associated with uric acid: evidence from humans and mice.

Authors:  Angelina R Sutin; Roy G Cutler; Simonetta Camandola; Manuela Uda; Neil H Feldman; Francesco Cucca; Alan B Zonderman; Mark P Mattson; Luigi Ferrucci; David Schlessinger; Antonio Terracciano
Journal:  Biol Psychiatry       Date:  2013-04-10       Impact factor: 13.382

9.  Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration.

Authors:  Xiqun Chen; Thomas C Burdett; Cody A Desjardins; Robert Logan; Sara Cipriani; Yuehang Xu; Michael A Schwarzschild
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-17       Impact factor: 11.205

Review 10.  Mitochondria-targeted antioxidants for treatment of Parkinson's disease: preclinical and clinical outcomes.

Authors:  Huajun Jin; Arthi Kanthasamy; Anamitra Ghosh; Vellareddy Anantharam; Balaraman Kalyanaraman; Anumantha G Kanthasamy
Journal:  Biochim Biophys Acta       Date:  2013-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.